BACKGROUND Type 2 diabetes mellitus (T2DM) is associated with an enhanced propensity for ventricular
T ype 2 diabetes mellitus (T2DM) is a multifactorial disease process that encompasses hyperglycemia, dyslipidemia, and hyperinsulinemia. Collectively, these factors produce a malignant environment marked by oxidative stress (1) . Although patients with T2DM are more vulnerable to ischemic injury than nondiabetic people (2) , the detailed electrophysiological substrate of T2DM hearts and their response to ischemia are poorly defined.
Because T2DM affects multiple organ systems, its pharmacological management is fraught with cardiovascular complications (3, 4) . One promising strategy is the use of the potassium channel agonist diazoxide (DZX), which improves the metabolic function of Otsuka Long-Evans Tokushima fatty rats by restoring their triglyceride and free fatty acid levels and reversing their weight gain and diabetes status (5) .
The antidiabetic efficacy of DZX is linked to preservation of pancreatic beta cells through promotion of beta cell rest and inhibition of apoptosis (5) . These mechanistic studies in animal models are being rapidly translated to humans. In a proof-of-principle trial, healthy people who received oral DZX (4 mg/kg) exhibited a 30% decrease in glucose production, with no difference in the rate of glucose uptake compared with placebo-treated counterparts (6) . Moreover, DZX reversed weight gain in prediabetic obese, hyperinsulinemic people (7, 8) . The therapeutic utility of DZX was also tested in patients with type 1 diabetes mellitus (T1DM) (9) and in those undergoing coronary bypass surgery (10). Radtke et al. (9) reported that treatment of newly diagnosed T1DM patients with DZX for 6 months improved their glycemic control without affecting their beta cell function. Finally, in a double-blinded randomized study, supplementation of cardioplegia with lowdose DZX protected cardiac mitochondria, metabolism, and function in patients undergoing cardiac bypass surgery (10) .
These highly encouraging clinical findings likely stem from the activation of cardioprotective signaling via mitochondrial adenosine triphosphate-sensitive potassium (mK ATP ) channels by DZX (11) (12) (13) (14) (15) (16) (17) (18) (19) . However, at high concentrations (300 mmol/l), DZX was shown to promote arrhythmias in coronary-perfused atria and ventricles from failing and nonfailing human hearts by activating sarcolemmal (as opposed to mitochondrial) K ATP channels (20) .
We hypothesized that owing to its dual nature as an antidiabetic and cardioprotective agent, low-dose (30 mmol/l) DZX may be particularly useful in suppressing ischemia-related arrhythmias in T2DM without altering basal electrophysiology. Contrary to our original hypothesis, we uncovered a potent proarrhythmic effect of DZX exclusively in T2DM hearts during challenge with ischemia. Our findings raise major concerns regarding the safety profile of mK ATP channel activation in T2DM patients at risk of ischemic injury. Preparations were placed in a custom-built tissue bath and pressed gently against a glass imaging window by a stabilizing piston (22) (23) (24) (25) (26) . Movement was suppressed by perfusion with blebbistatin 10 mmol/l for 10 to 15 min. To avoid surface cooling, preparations were immersed in the coronary effluent maintained at a physiological temperature by a heat exchanger assembly (22) . Cardiac rhythm was monitored continuously via silver electrodes connected to an electrocardiogram amplifier. Cardiac rhythm, perfusion pressure, and flow were monitored continuously during each experiment. Xie et al. STATISTICAL ANALYSES. Summary data are presented as mean AE SD. Welch's unpaired t test was used to detect differences in blood glucose levels between T2DM and controls. The Student t test was used to compare electrophysiological parameters between T2DM and control hearts. The paired t test was used to compare groups before and after drug treatment. One-way analysis of variance was used to compare differences between more than 2 groups.
S E P T E M B E R
A Fisher exact test was used to compare differences in susceptibility to arrhythmias. Differences were considered significant at p < 0.05.
RESULTS

BASAL ELECTROPHYSIOLOGICAL PROPERTIES OF
T2DM AND CONTROL ANIMALS. Xie et al.
Diazoxide-Mediated Arrhythmias in Diabetes was more severe in hearts from T2DM rats compared with control animals. Figures 2A and 2B show representative action potential traces and APD contour maps measured from control (SprD, ZL) and T2DM
(ZO) hearts before and 12 min after no-flow ischemia.
As expected, no-flow ischemia resulted in significant APD shortening in hearts from control animals (Figures 2A to 2C) . In sharp contrast, hearts from T2DM animals did not undergo progressive APD adaptation in response to an identical ischemic challenge (Figures 2A to 2C ). Instead, they exhibited a biphasic response, because early APD shortening was fully reversed during the latter phase (9 to 12 min) of ischemia ( Figure 2D ).
We next investigated potential differences in ischemia-mediated conduction slowing between groups. Figure 3A shows isopotential contour maps recorded at 1-ms intervals before (baseline) and 12 min after ischemia in control (SprD, ZL), and T2DM (ZO)
hearts. Figure 3B shows representative action potential upstrokes (first derivatives) measured from equidistant sites. Figure 3C presents average CV during baseline perfusion and after ischemic challenge. As expected, ischemia resulted in significant CV slowing in all groups. Interestingly, a trend toward a greater percentage reduction of CV by ischemia was noted for T2DM rats than for controls ( Figure 3D) ; however, this trend did not reach statistical significance (p ¼ 0.243). showing sustained shortening in the former group (purple) and a biphasic response in the latter (red). Superimposed action potential traces from representative T2DM (red) and control (purple) hearts at 12 min of ischemia. Controls consisted of SprD (n ¼ 3) and ZL (n ¼ 6) animals; T2DM was ZO animals (n ¼ 4). APD ¼ action potential duration; other abbreviations as in Figure 1 .
Finally, after the 12-min ischemia protocol, 4 of 9 control and 3 of 5 T2DM hearts underwent sustained arrhythmias within 1 min of reperfusion (not shown).
DZX PARADOXICALLY PROMOTES ARRHYTHMIAS IN
T2DM. The main purpose of our study was to determine whether low-dose DZX, which improves metabolic function in experimental models and in humans, would prevent arrhythmias in T2DM. We therefore examined its effects on key electrophysiological properties before and during challenge of T2DM hearts with ischemia. CV after 12 min of ischemia relative to baseline in control and T2DM (ZO) hearts. Controls were SprD (n ¼ 3) and ZL (n ¼ 6) animals; T2DM was ZO animals (n ¼ 4). Abbreviations as in Figure 1 .
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Diazoxide-Mediated Arrhythmias in Diabetes ventricular tachyarrhythmia (VT) during the latter phase (10 to 12 min) of ischemia ( Figure 4C) . Moreover, none of the 9 untreated or 7 DZX-treated control hearts exhibited VT during ischemia ( Figure 4C ).
As such, DZX provoked VT exclusively in T2DM hearts during ischemia ( Figure 4C ). Figure 4D hearts. In all cases, APD 75 of untreated T2DM hearts was longer after 12 min of ischemia than that of DZXtreated T2DM hearts, which underwent a 26% to 56% reduction before the onset of VT.
We investigated the potential mechanism underlying the selective proarrhythmic effect of DZX on T2DM
hearts. Whereas on average, DZX-treated T2DM hearts exhibited a minor trend toward longer APD 75 values during ischemia than DZX-treated controls, differences were not statistically significant ( Figure 5A ). In contrast, APD heterogeneity, as indexed by the standard deviation and range of APD 75 values across the mapping field, was more than 2-fold greater in DZXtreated T2DM than in DZX-treated control hearts at 8 and 10 min of ischemia ( Figure 5A ). Figure 5B shows representative APD contour maps that illustrate the greater APD heterogeneity at 8 min of ischemia in DZX-treated T2DM than in control hearts. Figure 5C shows representative histograms that illustrate the wider distribution of APD 75 values in individual DZXtreated T2DM hearts than in their control counterparts. Figures 1 and 3 .
Diazoxide-Mediated Arrhythmias in Diabetes levels of all known K ATP channel subunits using realtime PCR. Figure 7A shows the normalized (to betaactin) mRNA expression of the alpha (Kir6.1 and Kir6.2) and beta (SUR1A, SUR1B, SUR2A, and SUR2B) subunits of the K ATP channel in SprD, ZL, and ZO hearts. We found that samples from ZL and ZO animals exhibited a trend toward increased expression of most K ATP channel subunits compared with their SprD counterparts ( Figure 7A) ; however, this apparent up-regulation only reached statistical significance in the case of SUR2B between ZO and SprD animals ( Figure 7A) . Importantly, there were no significant differences in the expression of any of these subunits between ZL and ZO hearts ( Figure 7A ).
As such, none of the observed changes could explain the proarrhythmic effect that was exclusive to ZO animals.
A recent study highlighted the potential importance of ROMK (KCNJ1) in formation of the mK ATP channel (27). We therefore measured the mRNA levels of the 2 ROMK isoforms (ROMK1 and ROMK2) that are expressed in the heart. We found no significant differences in the expression levels of either isoform between groups ( Figure 7B ). Primers used for mRNA measurements are shown in Figure 7C .
DISCUSSION
We investigated the electrophysiological consequences of ischemia in T2DM and tested whether lowdose DZX, a potent activator of cardioprotective signaling (11) (12) (13) (14) (15) (16) (17) (18) (19) , could improve electrical function in that setting. Our major findings were as follows: 1) during normoxic perfusion, T2DM hearts are stable, exhibiting only minor electrophysiological changes;
2) in response to ischemia, T2DM hearts are characterized by repolarization resistance, because their average APD fails to exhibit progressive shortening;
3) DZX treatment exacerbates arrhythmias exclusively in T2DM hearts by promoting rapid and heterogeneous APD shortening during ischemia We measured the transcript levels of all known alpha and beta subunits of K ATP channels, including Kir6.1, Kir6.2, SUR1A, SUR1B, SUR2A, SUR2B, ROMK1, and
ROMK2. An important advantage of our experimental design was the use of 2 different control groups that were functionally identical but genetically distinct.
Specifically, ZL controls share a common genetic background with their ZO counterparts but are functionally identical (in terms of electrophysiology, heart weight, body weight, and blood glucose levels) to age-matched SprD animals. By measuring changes in The proarrhythmic effect of mitochondrial adenosine triphosphate-sensitive potassium (mK ATP ) channel activation by low-dose diazoxide (DZX) in hearts from rats with type 2 diabetes mellitus (T2DM) is illustrated. Electrophysiological properties were stable at baseline but revealed impaired adaptation to increased metabolic demand during acute ischemia in diabetic (red) compared with nondiabetic (blue) rats. The classically cardioprotective agent DZX caused paradoxical exacerbation of arrhythmias in diabetic but not normal animals, owing to a rapid and spatially heterogeneous shortening of action potentials across the heart, which in turn, created a substrate for reentrant ventricular tachyarrhythmia. APD ¼ action potential duration; APD 75 ¼ action potential duration at 75% of repolarization.
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